Alnylam's 10-Q for the quarter ended September 30, 2026 says the University of Texas System's patent suit over Onpattro now sits in Massachusetts, with trial set for August 2027. Alnylam is the plaintiff in two patent suits against Cipla, and a U.S. Attorney's Office subpoena on pricing records is open.
Ligand sued Viking on May 19, 2026 after purporting to end the TR-Beta license. Viking cross-sued Ligand and Metabasis. A hearing on Ligand's demurrer is set for February 26, 2027.
The ITC affirmed sanctions against Ascletis Bioscience, Gannex, Ascletis Pharmaceuticals, Ascletis Pharma and Jinzi Jason Wu in May 2025. Both sides appealed, and argument is expected in Q4 2027.
A Delaware federal court granted summary judgment of non-infringement for Teva and Apotex in September 2026. Vanda is weighing its options, and its 10-Q also reports a DOJ notice and new generic-drug suits.
Indivior Pharmaceuticals, Inc. is the named defendant in the Northern District of Ohio MDL. Canadian class actions name subsidiaries, and a qui tam case names Indivior Inc.
Stout v. Skye Bioscience alleges misleading statements about nimacimab from November 4, 2024 to October 3, 2025. Two derivative suits captioned against Dhillon are stayed, and consolidation was sought on August 11.
A jury found for former employee Wendy Cunning in 2023. The Ninth Circuit vacated the judgment in 2024. Skye now estimates the legal contingency at $5,417,250 and cites settlement talks.
The 10-Q says the patent claims and Hikma's antitrust claims are to be dismissed with prejudice under settlements agreed on Oct 13. It also lists antitrust complaints from Dr. Reddy's, Teva and Apotex in New Jersey.
The first class action was filed shortly after the FDA's first RP1 complete response letter. A motion to dismiss it is due to be fully briefed in December; the SEC closed its probe in June without recommending action.
A purported stockholder sued Beta Bionics and certain executive officers in a California federal court in September. The company says a loss is not currently probable nor estimable.
The 2023 Pembroke Pines suit over FDA findings at the Boston plant is still being contested after a supplemental amended complaint. Two derivative suits are stayed behind it.
The suit, filed in the Supreme Court of Victoria, covers investors who bought CSL securities between February 2025 and May 2026. CSL denies liability and says it will defend the case.
Defendants: Medpace Holdings, August J. Troendle, Jesse J. Geiger and Kevin M. Brady. Plaintiff filed a voluntary dismissal without prejudice on October 12, and a derivative suit was also dropped.
A Delaware suit naming Casdin Capital and SomaLogic directors is set for a March 2027 bench trial. SRS had claimed up to $17.5 million in Palamedrix milestones; that matter is resolved and the company paid Illumina $7.5 million on its indemnity.
Carew v. Lifecore Biomedical names the company and unnamed executive officers. The final approval hearing was held on July 28, 2026. A separate New York suit by 22NW Fund continues against the company.
The appeals court sent the Texas case back for new class certification proceedings. A $31.25 million settlement was filed in June, and Remi Barbier and Lindsay Burns, named in the 10-Q, are not parties to it.
Curanex Pharmaceuticals is a defendant, with underwriters Dominari Securities LLC, Pacific Century Securities, LLC and Revere Securities LLC, in two New York class actions over its August 2025 IPO. Both suits allege Securities Act violations in the offering documents.
The drugmaker ends its Nucynta license and royalties with Grünenthal and gets certain patents assigned to it. Grünenthal has filed a motion to dismiss the New Jersey case.
The 8-K says the New Jersey case followed Navinta's generic application. Navinta gets a royalty-free license from January 1, 2033; suits against other filers continue.
Supernus (Nasdaq: SUPN) took on Sage's New York class action naming Barry Greene and Kimi Iguchi, three derivative suits against sixteen unnamed insiders, and an SEC subpoena. Supernus faces two merger suits of its own.
The case names Actinium and executives Sandesh Seth, Avinash Desai, Madhuri Vusirikala and Sergio Giralt. Four derivative suits against directors and officers follow the same allegations.
Defendants: Jasper and unnamed current and former officers; derivative suits are captioned against Martell and others. A motion to dismiss was set for hearing October 15, and no ruling is reported.
The 8-K lists a net $175.0 million payment to UTC, a further $145.4 million in installments, and a YUTREPIA label change removing PH-ILD. Three parties are also paid to end the RareGen case, and one of them is a related party.
Lunai's 10-K says the Oct 7 demand covers all pending litigation. The Chancery case alleges breach of a 2018 investor rights agreement, and mediation has not been scheduled.
Lunai's 8-K asks Nasdaq to suspend trading, citing records from its Delaware suit. A later 8-K says trading will be suspended on October 30 unless the company asks for a hearing, and it does not plan to ask.
Atlas Merchant Capital agreed to dismiss its Chancery Court claims with prejudice, the hearing health company says. Two former executives were also named as defendants.
A federal court dismissed the Michigan class action with prejudice on August 10, 2026 and plaintiffs have appealed. A Minnesota Securities Act class action and a Michigan derivative suit remain pending.
Inovio, CEO Jacqueline Shea and CFO Peter Kies are defendants in a Pennsylvania class action. Shea, Kies and seven directors are named in derivative suits. A lead plaintiff was appointed July 27, 2026.
Dr. Reddy's told Tonix on October 1, 2026 that it filed an ANDA for a generic version of TONMYA 2.8 mg sublingual tablets and certified that four Orange Book patents are invalid, unenforceable or not infringed. No lawsuit has been filed, and Tonix says it intends to enforce its rights.
Defendants: Lantheus Holdings and unnamed Board members, per the 8-K. Two New York and one Massachusetts complaint allege proxy omissions; the company says they lack merit.
Unicycive disclosed in an 8-K dated September 28, 2026 that a second securities class action was filed on September 3, 2026 against the company and certain of its officers over its oxylanthanum carbonate application. An earlier class action and two derivative suits are pending in the same federal court.
A federal jury found that Eli Lilly breached the implied covenant of good faith in a rezpegaldesleukin license with Nektar and awarded $90 million, according to an 8-K filed September 25, 2026. Nektar is also a defendant in a securities class action, Schramke v. Nektar Therapeutics, filed in March 2026.
The class action names Sarepta, Douglas Ingram, Louise Rodino-Klapac and Ian Estepan. Derivative suits name eight directors. A $39.0 million patent settlement with REGENXBIO followed on September 23, 2026.
Aytu (Nasdaq: AYTU) is the plaintiff against Granules Pharmaceuticals in Delaware, with trial moved to January 12, 2027. It is also a nominal plaintiff in a Section 16(b) suit against Armistice, now on appeal.
AnaptysBio sued TESARO, Inc. and GSK on Nov. 20, 2025 over the dostarlimab collaboration. Trial ended July 17, 2026, and post-trial argument is set for Oct. 20. Tesaro's claim that AnaptysBio breached its duties was dismissed April 24.
Modica v. Aquestive names the company and chief executive Daniel Barber in New Jersey federal court. A derivative suit, Wilson v. Brown, is stayed behind it.
A purported stockholder sued Beta Bionics and certain executive officers in federal court in California, alleging misstatements about iLet. The company says it intends to defend and that any loss is not currently probable or estimable.
Cardiff Oncology settled its lawsuit against Nerviano Medical Sciences, the licensor of its lead drug onvansertib, on September 14, 2026. The case is dismissed with prejudice and the license is amended. Nerviano was the only defendant in the suit.
Nine individuals are named in the derivative suit: Baker, Biggar, Soland, Brege, Davis, Garofalo, Daly, Harrigan and Srdjan (Serge) Stankovic. The class action names Acadia and unnamed officers.
Joseph Gunnar and Lucosky Brookman sued Nutriband, CEO Gareth Sheridan, President Serguei Melnik, Vitalie Botgros, TII Jet Services and Wolf Blitz in 2023 over a terminated offering engagement. Nutriband denies the claims and has counterclaimed.
Abbott Laboratories, a defendant in numerous NEC lawsuits, agreed to resolve the Gill case, where a jury awarded $495 million, and claims for about 2,000 other infants. About 1,700 lawsuits remain pending.
Dodge v. Mereo Biopharma Group PLC (1:26-cv-988) was filed Feb. 4, 2026 in the Southern District of New York. The lead plaintiff filed an amended complaint on July 13, 2026.
The New Jersey court dismissed the second amended complaint in part on Dec. 23, 2025, and plaintiffs refiled. Outlook and certain unnamed officers are defendants; a Delaware derivative suit is stayed.
Exicure's securities class action and its shareholder derivative suits are over, according to a quarterly report filed August 14, 2026. The class action settled for $5.625 million, funded by insurers, and the derivative suits were dismissed in June 2026 after court approval.
A Securities Act suit in New York names Neumora, certain executive officers and certain underwriters. Defendants' reply on their motion to dismiss the second amended complaint is due August 24, 2026.
GT Biopharma is the only defendant named in New York suits by Z-One, Silberfein, DiPietro and the Werthman Trust. Z-One's claims were dismissed and appealed. The other three are in settlement talks.
A Northern District of California class action names Vistagen, CEO Shawn Singh and COO Joshua Prince. Two derivative suits are stayed behind it, and a separate pro se case was dismissed with prejudice on August 12.
BE&K Building Group sued HCW Biologics, Cogent Bank and subcontractors in Broward County over unpaid renovation invoices. Fisk Electric's suit was consolidated, and Cogent Bank has demanded the liens be cleared.
The Federal Circuit affirmed on Aug. 4, 2026 that Aveva's generic does not infringe Scilex's ZTlido patents. Defendants were Aveva Drug Delivery Systems, Apotex Corp. and Apotex, Inc.
Mevi et al. v. Ji et al. names Scilex, Semnur and others not listed in the 10-Q. The court stayed the case on June 25, 2026; Scilex's filings do not identify the other defendants.
Defendants: Capricor and unnamed officers in the new July 30 class action, and Capricor and CEO Linda Marbán in the 2025 one. The FDA also moved the deramiocel date to November 22, 2026.
Cytokinetics (Nasdaq: CYTK) filed a complaint on August 13, 2026, seeking a declaratory judgment that it does not infringe U.S. Patent No. 12,616,697 and that the patent's claims are invalid. The defendants are Bristol-Myers Squibb and MyoKardia.
Kyntra Bio, formerly FibroGen, says it must advance legal costs for an SEC case against its former chief medical officer and may have to cover some costs and judgments. It had accrued about $7.0 million for those obligations at June 30, 2026, up from an amount it called not material three months earlier.
Calidi, director and ex-CEO Allan Camaisa and ex-officer Ms. Pizarro are defendants in San Diego employment suits. Investor Yian Zeng's federal case against Calidi had a summary judgment hearing set for Aug 24, 2026.
The class action names CorMedix and six officers, including Khoso Baluch. A settlement of derivative suits naming 12 individuals had a final approval hearing set for September 23, 2026.
Alumis (Nasdaq: ALMS) inherited Boukadoum v. Acelyrin in its May 2025 merger. The filing names ACELYRIN and unnamed officers and directors; ACELYRIN's 2024 signers are listed.
AptarGroup and Aptar France sued ARS Pharmaceuticals and ARS Pharmaceuticals Operations in March 2025. The company's separate antitrust suit against AptarGroup was moved to New York in July 2026.
A stockholder sued the company and unnamed current and former officers in the Southern District of California on August 5, 2026. A pharmacy filed a separate fax-advertising class action in July.
The 10-Q says Fate and unnamed officers are defendants in a Southern District of California class action. The derivative suits are captioned against Wolchko; board lists come from Fate's 2023 and 2026 proxies.
The 10-K says the court certified the class on June 18, 2026 in In re BioVie Inc. Securities Litigation. BioVie and unnamed officers are defendants; insurance carries a $2 million deductible.
Kinnamon v. Gossamer Bio names the company and unnamed executive officers and directors over a June 16, 2025 to February 20, 2026 class period. The 10-Q gives no loss estimate.
A federal court in California dismissed the securities class action over Alto Neuroscience's ALTO-100 disclosures on August 7, 2026, and gave the plaintiffs leave to file a third amended complaint. A related derivative action has been stayed.
Inovio sued VGXI, Inc. and GeneOne Life Science, Inc. in a Pennsylvania state court in 2020 over a supply agreement. The defendants counterclaimed. A seven-day trial was scheduled to begin October 13, 2026.
The SEC fined former CEO Ankit Mahadevia $112,500 and former CFO Satyavrat Shukla $75,000 in a settled January 2026 order. Spero's letter of Jan 20, 2026 says the SEC does not intend to recommend action against it.
The North Carolina class action names Humacyte and certain officers. Derivative suits name current or former directors and officers, and Ayabudge LLC in two cases. Product safety claims survived dismissal.
Kuang v. Atara, filed in Central District of California, names the company and unnamed current and former officers. An amended complaint came on August 10, and defendants must respond by October 9.
Kyverna Therapeutics is defending a Securities Act class action over its February 2024 IPO, which names the company, certain officers and directors, and the underwriters. A second amended complaint is under a motion to dismiss, with a hearing set for September 3, 2026. Two derivative suits filed in May 2025 were later consolidated.
Stockholders sued in Delaware Chancery over the August 2023 private placement. A special litigation committee moved on March 3, 2026 to end the case, and the lead plaintiff does not oppose.
TherapeuticsMD (Nasdaq: TXMD) sued Mayne Pharma LLC in Delaware over net working capital allowances and faces a countersuit. Teva and Sun Pharma are defendants in New Jersey patent cases over generic IMVEXXY.
Erasca (Nasdaq: ERAS) is named in a June class action in San Diego federal court. An August derivative suit names its current directors and CFO. The 10-Q names no officers in the class action.
Y-Trap, Inc. sued Bicara Therapeutics and Biocon Ltd in Massachusetts federal court in October 2024. Discovery is ongoing, and a patent office review Bicara requested was instituted on July 15, 2026.
Warrant holder Andrew Schwartzberg seeks more than $3.1 million from Gain and Gene Mack for breach of contract, fraudulent inducement and promissory estoppel. Gain's 10-Q reports going concern doubt.
Veru, Chairman and CEO Mitchell Steiner and CFO Michele Greco are defendants in a Florida class action. Five derivative suits name seven officers and directors. Veru says it cannot estimate losses.
Clear Future, Inc. sued Veru Inc. in Delaware Superior Court after buying the FC2 female condom business for $18.0 million in cash. Veru is the defendant named in the 10-Q and says it cannot estimate losses.
The Washington federal suit names Sana (Nasdaq: SANA), CEO Steven D. Harr and former CFO Nathan Hardy over SC291 statements. A second amended complaint was filed May 26, 2026, and the case is stayed.
Ho and Yankov complaints named Rocket, CEO Gaurav Shah and former CFO Aaron Ondrey. Rocket's motion to dismiss the consolidated complaint is pending, and a derivative suit is stayed.
Vreeland v. Metagenomi names the company, unnamed officers and directors under Section 11. The court partly denied dismissal on March 24, 2026; the S-1 shows who signed.
Stockholders sued Axsome's directors and officers in New York and Delaware over AXS-07 statements. Delaware dismissed with prejudice on July 9, 2026. The New York motion to dismiss is fully briefed.
Axsome's 10-Q says it has settled with every current Sunosi ANDA filer, the last being Aurobindo on June 2, 2026. Its Symbravo patent suit against Apotex Inc. is in fact discovery.
The Peters suit names MoonLake and its chief executive, chief financial and chief scientific officers. The class period runs March 10, 2024 through September 29, 2025.
Paul Feller sued RestorGenex, Pro Sports & Entertainment, ProElite and Stratus Media Group, GmbH in Los Angeles. The court dismissed some claims on March 26, 2026. CervoMed says it is defending itself vigorously.
A jury found Natera liable in November 2024 in the Northern District of California. Final judgment came in June 2026 and Natera is appealing to the Ninth Circuit.
The District of Massachusetts dismissed In re Agenus Inc. Securities Litigation on March 24, 2026. The lead plaintiff appealed to the First Circuit, where briefing began in June. Derivative suits remain stayed.
A Delaware court denied ANI's bid for a new trial against CG Oncology on July 16, and ANI plans to appeal. In Minnesota, ANI is defending Acella's Lanham Act suit, with summary judgment argument set for August 25.
Orphalan sued Novitium, and Xeris and Strongbridge sued Novitium and ANI. In a Harmony patent case against AET and Sandoz entities, the defendants counterclaim against Harmony and Novitium.
Cronin v. Merck in New Jersey names Merck and unnamed officers. The 10-Q gives no individual defendants; Merck's filings show its CEO, CFO and 13 director nominees.
Defendants: aTyr Pharma, CEO Sanjay Shukla and, since May, CFO Jill M. Broadfoot. The July 17 motion to dismiss targets the amended complaint; aTyr committed on August 7 to cut 60% of staff.
Yarborough v. Ardelyx named the company and executives Michael Raab, Susan Rodriguez, Laura Williams and Elizabeth Grammer. The First Circuit appeal was dismissed on March 26, 2026.
Gilead, Bristol-Myers Squibb, Johnson & Johnson and Teva are defendants in consolidated federal suits over HIV drugs. Gilead paid $525 million in 2023 to settle with the direct purchaser class and retailer opt-out plaintiffs.
The 10-Q names Gilead as defendant, with no co-defendants listed, in a putative class action and product liability suits over Viread, Truvada, Atripla, Complera and Stribild. A federal bellwether trial is set for March 2027.
Iovance (Nasdaq: IOVA) and unnamed officers are defendants in a California class action over 2025 revenue guidance. Derivative suits against Frederick Vogt, Jean-Marc Bellemin and others are stayed. Iovance has moved to dismiss.
Iovance (Nasdaq: IOVA) is a nominal defendant in two Court of Chancery suits against its directors. A 2020 pay suit is consolidated and a 2024 offering suit is in motion-to-dismiss briefing.
A Massachusetts court fully granted dismissal of the Gonzalez suit against Intellia (Nasdaq: NTLA) and unnamed officers on June 18, 2026. A Delaware suit against directors and BlueAllele's patent suit remain open.
Viatris (Nasdaq: VTRS) and unnamed current and former officers are defendants in a Pennsylvania class action over Indore disclosures. Derivative suits name officers and directors in Pennsylvania and Delaware.
Hayes v. Borisy, filed December 2024, names Borisy and other directors and officers of Relay (Nasdaq: RLAY) that the 10-Q does not list. The case is in discovery and Relay cannot predict the outcome or any loss.
The Federal Circuit affirmed on July 9, 2026 that the asserted patent claims are invalid. Wyeth, the Pfizer subsidiary and co-plaintiff, had won a $107.5 million jury award against AstraZeneca Pharmaceuticals LP and AstraZeneca AB.
Puma is suing Hedrick Gardner Kincheloe & Garofalo, L.L.P. and attorney David L. Levy over its defense in the Eshelman case. The Court of Appeals revived the claim on Sept. 3, 2025.
The 10-Q says the defendants in the Pennsylvania class action are the company and "certain of its agents" and names none. Derivative suits in two courts are stayed, and a Delaware class action over the charter was dismissed as moot.
Arcturus filed in the Southern District of California on September 23, 2025. Capstan Therapeutics answered with counterclaims against the company and two employees, and no trial date is set.
The 10-Q says the Karam suit against PepGen, its CEO and its CFO was voluntarily dismissed on Nov. 18, 2025. The filing does not name the officers; the 2023 annual report shows McArthur and Donnelly.
Defendants: Verrica and unnamed current and former officers and directors. A July term sheet would end a case certified in March; Verrica accrued $4.0 million and needs court approval.
The 10-Q names Perrigo, CFO Eduardo Bezerra and former CEOs Patrick Lockwood-Taylor and Murray Kessler in French v. Perrigo. A Teamsters pension fund is lead plaintiff and filed an amended complaint on May 1, 2026.
BioAge Labs' 10-Q says a federal court dismissed the IPO securities class action with prejudice on March 2, 2026, and the plaintiff has appealed to the Ninth Circuit. The defendants are BioAge, its directors and certain officers, and the filings do not name the officers.
Geron is a defendant in a consolidated securities class action over statements about RYTELO, and four derivative suits repeat the claims. The class action was dismissed without prejudice on March 30, 2026, and a second amended complaint is now under a motion to dismiss.
The Court of Chancery dismissed Nemeth v. Casdin with prejudice on June 18, 2026 after a settlement. Revolution was named only as successor to EQRx, alongside its director Alexis Borisy and others.
The Vladimir Gusinsky Revocable Trust sued Context and its directors on February 4, 2026. A consent judgment voided two charter provisions, and a third party paid plaintiff's counsel $850,000.
Amgen, CEO Robert Bradway and CFO Peter Griffith agreed to settle the New York class action, subject to court approval. Derivative suits against directors are stayed.
Homyk v. ChemoCentryx named ChemoCentryx and its CEO over TAVNEOS statements. A California federal court preliminarily approved a class settlement on June 12, 2026; final hearing is October 29.
BioCryst filed the patent suit on March 10, 2025 after Paragraph IV notices from Annora Pharma. The 10-Q says the case is in early stages and no estimate of loss is possible.
Industry Office SLC sued Recursion in 2023 for breach of contract; Recursion counterclaimed for breach and fraudulent misrepresentation. Both sides are in discovery. An Exscientia class action ended in December 2025.
Acadia is the plaintiff against Aurobindo, MSN, Teva and Zydus entities. A June 2025 judgment for Acadia is on appeal, and a new Zydus case goes to trial November 2, 2026.
Mirum, Satiogen and Shire Human Genetic Therapies are plaintiffs in four consolidated cases. A 30-month FDA stay runs through March 29, 2029, and the Markman hearing is April 21, 2027.
Niagen and its ChromaDex subsidiary are sued in two consumer class actions and a Thorne patent case. A Federal Circuit ruling on a $9.2 million fee award to Elysium is pending.
Ionis sued Arrowhead in California on Sept. 11, 2025 over the '333 patent. Arrowhead, the only named defendant, disputes the claim; its Delaware declaratory action was dismissed Dec. 23, 2025.
Thomas and Kent v. Reneo name Reneo and unnamed individual defendants. The 10-Q says plaintiffs have not pursued the claims; the 2024 proxy lists Reneo's board.
The company and certain employees received Justice Department subpoenas in early 2025. A Delaware derivative suit over non-employee director pay has a fairness hearing set for September 14, 2026.
Jonathan Forman says he conceived of inventions claimed in two U.S. patents and was wrongly left off as an inventor. Krystal is the named defendant and says the claims are without merit.
Sage Chemical and TruPharma sued Supernus, Britannia, US WorldMeds and others in Delaware. Four individuals were dismissed in 2024. Insurance coverage suits tied to an unnamed Delaware action are open.
EyePoint, Inc. sued Ocular in Massachusetts state court on March 20, 2026 over alleged false statements about DURAVYU. The court denied a restraining order on April 13 and has not ruled on a preliminary injunction.
Teamsters Local 710 leads a consolidated New Jersey class action against Organon and unnamed officers. Two derivative suits are stayed, and a July 6 suit against the board and Sun Pharma entities challenges the merger proxy.
Bristol Myers Squibb's 10-Q says the company and certain Sanofi entities are defendants in a Texas state suit over Plavix labeling, sales and promotion. Arkansas has sued BMS over 340B contract pharmacy policies, and a Celgene securities class action settled with final approval in May 2026.
Bristol Myers Squibb's 10-Q says it sued seven generic drugmakers in the U.S. District Court for the District of Delaware over Camzyos patents. The defendants are Aurobindo, Zenara, Micro Labs, Dr. Reddy's, Annora, Apotex and MSN. The filing gives no case numbers, filing dates or rulings.
Suits in Illinois federal court allege misleading statements about Baxter's Novum LVP pump. The 10-Q names Baxter and unnamed officers; the derivative captions name Jose E. Almeida.
Linet Americas sued Hill-Rom Holdings, Hill-Rom Company and Hill-Rom Services in 2021. A dismissed class action is on appeal, and a DOJ demand and subpoena remain open.
Two Alkermes subsidiaries filed Hatch-Waxman patent suits in New Jersey and Delaware against Teva Pharmaceuticals, Apotex and MSN entities. FDA approval of each generic application is stayed for up to 30 months.
Value Drug Company sued Alkermes, Inc. and Alkermes Pharma Ireland Limited in Massachusetts in October 2025. A December 2025 motion to dismiss is the latest step the 10-Q reports.
Rainaldi Revocable Trust sued certain current and former Summit directors in Delaware Chancery in 2025, with Summit a nominal defendant. The parties stipulated to dismissal on May 27, 2026.
Defendants: Silexion, chairman and CEO Ilan Hadar, and CFO Mirit Horenshtein Hadar. Moringa Sponsor disputes how Silexion converted part of a $3,433 thousand note into shares and alternatively demands cash; Silexion says it complied with the note.
The court ruled June 1, 2026 in Heron's patent suit against Azurity Pharmaceuticals and Slayback Pharma entities. Heron says it will appeal to the Federal Circuit and that the ruling does not affect a prior settlement.
Nerviano Medical Sciences told Cardiff on May 27, 2026 it was ending the License Agreement over a patent inventorship dispute. Cardiff, which sued NMS as defendant on May 19, says the notice is legally ineffective.
Defendants are SpyGlass Pharma and employee Long Doan. SpyGlass countersued Glaukos on May 22 over contract interference, and the court moved trial to January 2027.
Capricor Therapeutics filed a complaint in New Jersey seeking to rescind its January 24, 2022 distribution agreement and asking for a preliminary injunction. The FDA target action date for Deramiocel is August 22, 2026.
Under a license agreement, the lawsuit will be dismissed and Cipla will not sell a generic version in the U.S. until September 1, 2033, or earlier under specified circumstances. Each side bears its own costs.
Moderna agrees to pay a $950.0 million noncontingent lump sum and may owe a further $1.3 billion depending on a Federal Circuit appeal on 28 U.S.C. §1498. Arbutus is entitled to 20% of proceeds after litigation costs, or, if less, tiered low single-digit royalties.
Climb Bio filed a complaint in Delaware Superior Court against Alumis Inc. and Acelyrin, Inc. It asks for a declaration that budoprutug is not a Product under a 2024 asset purchase agreement, and that Climb does not owe a $3 million milestone payment.
Cassava and Chief Financial Officer Eric J. Schoen accepted a mediator's recommendation to settle the consolidated securities class action for $31.25 million. Remi Barbier and Lindsay Burns did not sign the term sheet but would receive releases once the court approves.
AnaptysBio's Verified Complaint of Nov 20, 2025 names Tesaro, Inc. and its parent GlaxoSmithKline and alleges breaches of the Jemperli collaboration. Tesaro sued AnaptysBio the same day, and the parties have agreed to ask for an expedited schedule.
Factor Bioscience sued Cellectis and AstraZeneca in Delaware federal court on Sept 26, 2025, over TALEN gene-editing technology. Allogene is not a party, but it licenses that technology from Cellectis and says Factor may still sue it directly.
Enanta Pharmaceuticals says it sued Pfizer Inc. and certain of its subsidiaries in the Unified Patent Court on Aug 20, 2025, alleging infringement of a European patent through Paxlovid sales. The claim is untested, and no hearing date is given.
Unicycive said a securities class action was filed in the Northern District of California against the company and certain of its officers, who are not named. The suit concerns statements about its oxylanthanum carbonate application. The company calls the claims meritless.
A federal court preliminarily approved the settlement of three shareholder derivative suits naming ImmunityBio's current and former officers and directors. The company agrees to governance reforms and expects its insurer to pay the plaintiffs' attorneys' fees, which their counsel plans to ask the court to set at up to $1,400,000. The final hearing is November 4, 2025.
A Delaware stockholder class action against Protalix BioTherapeutics and its board, Thomas v. Bashan, et al., was dismissed as to the plaintiff after the board amended the bylaws. Protalix agreed to pay $160,000 in fees and expenses to the plaintiff's counsel, and it denies the allegations.
Marcum LLP resigned as Cell Source's auditor on June 26, 2025, after CBIZ CPAs took over its attest practice. Marcum's reports on 2022 and 2023 carried a going-concern paragraph.
Lupin Limited gets a license to launch a generic WAKIX no earlier than January 2030, or July 2030 with pediatric exclusivity, and the Delaware case will be dismissed.
Taysha Gene Therapies agreed to sell 46,868,687 shares and pre-funded warrants for 25,858,586 more at $2.75 a share, with net proceeds estimated at $187.4 million. The company says that money and its existing cash will last into 2028, and the filing names no lawsuit or defendant.
The U.S. District Court for the District of Maryland granted preliminary approval on May 9, 2025 to a settlement of shareholder derivative suits against current and former Emergent directors and officers. The settlement provides a $15 million payment to the company from insurance and governance reforms, and final approval is set for August 6, 2025.
A federal court in Delaware ruled for Acadia on infringement and validity of the '721 patent against Aurobindo and MSN entities. The company also signed a lease of 12 years and two months for new Princeton offices.
The complaint alleges Liquidia infringes U.S. Patent No. 11,357,782 and seeks to bar Liquidia from commercializing YUTREPIA if approved. Liquidia says the claims mirror a patent that the Patent Trial and Appeal Board held invalid.
Arbutus Biopharma and Genevant Sciences sued Moderna, Inc. and a Moderna affiliate, which the filing does not name, over patents tied to the MRNA-1273 COVID-19 vaccine. On March 31, 2025 the court moved the patent trial from September 24 to September 29, 2025.
A federal judge in Washington denied Liquidia's summary judgment motion on February 27, 2025, upholding the FDA's three-year exclusivity for United Therapeutics' Tyvaso DPI. The exclusivity still ends May 23, 2025, and a related cross claim remains pending.
aibio
